Martin Shkreli Net Worth 2026#641 ENTREPRENEURS
Pharmaceutical Executive, Entrepreneur
Where the money comes from
Listed in the order our sources give them; the first is treated as primary. We do not publish a percentage split — no public breakdown of this person’s income exists, and inventing one would be a guess.
Is $70M a lot? — against entrepreneurs
Ranked #641 of 1,182 entrepreneurs we hold an estimate for.
Martin Shkreli, often referred to as the “Pharma Bro,” remains one of the most controversial figures in the pharmaceutical industry. He garnered international attention during his tenure as the CEO of Turing Pharmaceuticals, where he notoriously raised the price of the life-saving drug Daraprim from $13.50 to $750 per pill overnight. This comprehensive article aims to provide an updated and in-depth analysis of Martin Shkreli’s net worth as of 2024, considering his diverse sources of wealth, legal troubles, and potential future income.
Martin Shkreli’s financial journey is as controversial as his public persona. Born to Albanian immigrant parents in Brooklyn, New York, Shkreli’s early fascination with chemistry and the stock market steered him towards a high-profile albeit contentious career path. Initially starting as an intern for Jim Cramer’s hedge fund, Cramer Berkowitz & Co., Shkreli quickly rose through the ranks, eventually founding his own hedge fund, Elea Capital Management, in 2006.
Despite significant legal troubles that led to his incarceration, Martin Shkreli has managed to maintain a considerable net worth. As of 2024, Shkreli’s estimated net worth stands at approximately $27 million. His portfolio includes diverse investments in stocks, bonds, real estate, and cryptocurrencies. Although his assets were once valued much higher, multiple legal battles and asset forfeitures have significantly impacted his overall wealth.
Shkreli’s primary investments include his remaining stake in Turing Pharmaceuticals, which is estimated to be worth around $10 million. Additionally, he owns a portfolio diversified with stocks, bonds, and a substantial amount of cryptocurrency, which has seen notable appreciation over the years.
Among Shkreli’s most talked-about assets was the one-of-a-kind Wu-Tang Clan album “Once Upon a Time in Shaolin,” for which he paid $2 million. This and other high-value possessions were part of the $7.4 million he was ordered to forfeit due to his legal convictions.
At his peak in 2015, Martin Shkreli’s net worth was estimated at around $70 million. This figure reflects his successes in hedge fund management and pharmaceutical ventures. Adjusted for inflation, Shkreli’s peak net worth would be approximately $80 million in 2024 dollars. However, legal issues, including his 2017 conviction for securities fraud, had a substantial negative impact on his financial standing.
Martin Shkreli has often been vocal about his aggressive investment strategies and his belief in taking bold financial risks. He has consistently emphasized the importance of capitalizing on market inefficiencies and exploiting opportunities that many would overlook due to ethical considerations. Though not necessarily aligned with traditional personal finance advice, his approach mirrors that of high-risk hedge fund managers.
In today’s context, Martin Shkreli’s net worth pales in comparison to pharmaceutical magnates like Jeff Bezos of Amazon (due to Amazon Pharmacy), or other high-net-worth individuals in the pharmaceutical field. However, his controversial methods and media presence continue to make him a topic of public interest and conversation.